AI assistant
Jazz Pharmaceuticals plc — Director's Dealing 2022
Aug 3, 2022
30751_dirs_2022-08-03_2d9fed0e-546f-45df-bef1-72ae558ab38c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2022-08-01
Reporting Person: COZADD BRUCE C (Director, Chairman & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-08-01 | Ordinary Shares | M | 9632 | $46.83 | Acquired | 361544 | Direct |
| 2022-08-01 | Ordinary Shares | M | 68 | $59.13 | Acquired | 361612 | Direct |
| 2022-08-01 | Ordinary Shares | S | 2600 | $153.4816 | Disposed | 359012 | Direct |
| 2022-08-01 | Ordinary Shares | S | 2601 | $154.5015 | Disposed | 356411 | Direct |
| 2022-08-01 | Ordinary Shares | S | 1100 | $155.268 | Disposed | 355311 | Direct |
| 2022-08-01 | Ordinary Shares | S | 1000 | $154.94 | Disposed | 354311 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-08-01 | Non-Qualified Stock Option (right to buy) | $46.83 | M | 9632 | Disposed | 2022-08-08 | Ordinary Shares (9632) | Direct |
| 2022-08-01 | Non-Qualified Stock Option (right to buy) | $59.13 | M | 68 | Disposed | 2023-03-04 | Ordinary Shares (68) | Direct |
Footnotes
F1: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options.
F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $153.01 to $153.935. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $154.01 to $154.95. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $155.015 to $155.66. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F5: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F6: This Non-qualified stock option is part of an option granted on August 9, 2012. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016.
F7: This non-qualified stock option is part of an option granted on March 5, 2013. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of March 5, 2017.